Metabolomic studies of human gastric cancer: Review

World Journal of Gastroenterology

Volumn 20, Issue 25, 2014, Pages 8092-8101

  Jayavelu, Naresh Doni ^a   Bar, Nadav S ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Biomarkers; Chemosensitivity; Gastric cancer; Liquid gas chromatography and mass spectrometry; Metabolomics; Metastasis; Nuclear magnetic resonance spectroscopy

Indexed keywords

1 ACYL LYSOPHOSPHATIDYLCHOLINE; 2 OXOGLUTARIC ACID; ALANINE; ANTINEOPLASTIC AGENT; AZELAIC ACID; BIOLOGICAL MARKER; CITRIC ACID; CREATININE; GLUTAMINE; GLYCEROL; HIPPURIC ACID; HYDRACRYLIC ACID; INOSITOL; ISOLEUCINE; LACTIC ACID; MALIC ACID; PHOSPHOSERINE; POLYUNSATURATED FATTY ACID; PROLINE; PYRUVIC ACID; SARCOSINE; SERINE; SUCCINIC ACID; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG; URATE; VALINE; TUMOR MARKER;

ANALYSIS OF VARIANCE; CANCER DIAGNOSIS; CANCER PROGNOSIS; CAPILLARY ELECTROPHORESIS; CHEMOSENSITIVITY; DATA PROCESSING; HIGH THROUGHPUT SCREENING; HUMAN; INFRARED SPECTROSCOPY; K NEAREST NEIGHBOR; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLITE; METABOLOME; METABOLOMICS; METASTASIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PREDICTOR VARIABLE; PRINCIPAL COMPONENT ANALYSIS; RAMAN SPECTROMETRY; REVIEW; STOMACH CANCER; XENOGRAFT; GAS LIQUID CHROMATOGRAPHY; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTOMICS; ANIMAL; METABOLISM; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; STOMACH NEOPLASMS; SYSTEMS BIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; METABOLOMICS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; STOMACH NEOPLASMS; SYSTEMS BIOLOGY; TUMOR MARKERS, BIOLOGICAL;

EID: 84903975977     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i25.8092     Document Type: Review

References (111)

1. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 450-464 [PMID: 15297938]
2. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12: 354-362 [PMID: 16489633]
3. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods Mol Biol 2009; 472: 467-477 [PMID: 19107449 DOI: 10.1007/978-1-60327-492-0_23]
4. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9: 279-287 [PMID: 18308253 DOI: 10.1016/s1470-2045(08)70072-x]
5. Society AC. Global Cancer Facts and Figures. 2nd ed. Atlanta: American Cancer Society, 2011
6. Macdonald JS. Gastric cancer--new therapeutic options. N Engl J Med 2006; 355: 76-77 [PMID: 16822999 DOI: 10.1056/ NEJMe068121]
7. Cunningham D, Chua YJ. East meets west in the treatment of gastric cancer. N Engl J Med 2007; 357: 1863-1865 [PMID: 17978296 DOI: 10.1056/NEJMe078182]
8. Rajdev L. Treatment options for surgically resectable gastric cancer. Curr Treat Options Oncol 2010; 11: 14-23 [PMID: 20358316 DOI: 10.1007/s11864-010-0117-1]
9. Yilmaz M, Christofori G. Mechanisms of motility in metastasizing cells. Mol Cancer Res 2010; 8: 629-642 [PMID: 20460404 DOI: 10.1158/1541-7786.mcr-10-0139]
10. Tashiro A, Sano M, Kinameri K, Fujita K, Takeuchi Y. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol 2006; 12: 4873-4874 [PMID: 16937471]
11. Sipponen P, Ranta P, Helske T, Kääriäinen I, Mäki T, Linnala A, Suovaniemi O, Alanko A, Härkönen M. Serum levels of amidated gastrin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol 2002; 37: 785-791 [PMID: 12190091]
12. Lu X, Zhao X, Bai C, Zhao C, Lu G, Xu G. LC-MS-based metabonomics analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 866: 64-76 [PMID: 17983864 DOI: 10.1016/ j.jchromb.2007.10.022]
13. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol 2003; 98: 735-739 [PMID: 12738449 DOI: 10.1111/j.1572-0241.2003.07410.x]
14. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44: 693-697 [PMID: 10205207]
15. Väänänen H, Vauhkonen M, Helske T, Kääriäinen I, Rasmussen M, Tunturi-Hihnala H, Koskenpato J, Sotka M, Turunen M, Sandström R, Ristikankare M, Jussila A, Sipponen P. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003; 15: 885-891 [PMID: 12867799 DOI: 10.1097/01.meg.0000059169.46867.01]
16. Kikuchi S, Kurosawa M, Sakiyama T, Tenjin H, Miki K, Wada O, Inaba Y. Long-term effect of Helicobacter pylori infection on serum pepsinogens. Jpn J Cancer Res 2000; 91: 471-476 [PMID: 10835490]
17. Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 2004; 22: 245-252 [PMID: 15109811 DOI: 10.1016/j.tibtech.2004.03.007]
18. Rochfort S. Metabolomics reviewed: a new "omics" platform technology for systems biology and implications for natural products research. J Nat Prod 2005; 68: 1813-1820 [PMID: 16378385 DOI: 10.1021/np050255w]
19. Schmidt C. Metabolomics takes its place as latest up-andcoming "omic" science. J Natl Cancer Inst 2004; 96: 732-734 [PMID: 15150298]
20. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer 2004; 4: 551-561 [PMID: 15229480 DOI: 10.1038/ nrc1390]
21. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H, Kinoshita T, Saito N, Ochiai A, Tomita M, Esumi H, Soga T. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009; 69: 4918-4925 [PMID: 19458066 DOI: 10.1158/0008-5472. can-08-4806]
22. Klein CA. Cancer. The metastasis cascade. Science 2008; 321: 1785-1787 [PMID: 18818347 DOI: 10.1126/science.1164853]
23. Tan C, Chen H, Xia C. Early prediction of lung cancer based on the combination of trace element analysis in urine and an Adaboost algorithm. J Pharm Biomed Anal 2009; 49: 746-752 [PMID: 19150588 DOI: 10.1016/j.jpba.2008.12.010]
24. Hori S, Nishiumi S, Kobayashi K, Shinohara M, Hatakeyama Y, Kotani Y, Hatano N, Maniwa Y, Nishio W, Bamba T, Fukusaki E, Azuma T, Takenawa T, Nishimura Y, Yoshida M. A metabolomic approach to lung cancer. Lung Cancer 2011; 74: 284-292 [PMID: 21411176 DOI: 10.1016/j.lungcan.2011.02.008]
25. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH. Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics 2009; 8: 558-570 [PMID: 19008263 DOI: 10.1074/ mcp.M800165-MCP200]
26. Kind T, Tolstikov V, Fiehn O, Weiss RH. A comprehensive urinary metabolomic approach for identifying kidney cancerr. Anal Biochem 2007; 363: 185-195 [PMID: 17316536 DOI: 10.1016/j.ab.2007.01.028]
27. Gu H, Pan Z, Xi B, Asiago V, Musselman B, Raftery D. Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: Application to the detection of breast cancer. Analytica Chimica Acta 2011; 686: 57-63 [DOI: 10.1016/j.aca.2010.11.040]
28. Monleón D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortés O, Gil-Benso R, López-Ginés C, Cerdá-Nicolás M, Celda B. Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res 2008; 7: 2882-2888 [PMID: 18507434 DOI: 10.1021/pr800110a]
29. Monleón D, Morales JM, Barrasa A, López JA, Vázquez C, Celda B. Metabolite profiling of fecal water extracts from human colorectal cancer. NMR Biomed 2009; 22: 342-348 [PMID: 19006102 DOI: 10.1002/nbm.1345]
30. Mal M, Koh PK, Cheah PY, Chan EC. Development and validation of a gas chromatography/mass spectrometry method for the metabolic profiling of human colon tissue. Rapid Commun Mass Spectrom 2009; 23: 487-494 [PMID: 19140133 DOI: 10.1002/rcm.3898]
31. Qiu Y, Cai G, Su M, Chen T, Liu Y, Xu Y, Ni Y, Zhao A, Cai S, Xu LX, Jia W. Urinary metabonomic study on colorectal cancer. J Proteome Res 2010; 9: 1627-1634 [PMID: 20121166 DOI: 10.1021/pr901081y]
32. Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S, Jia W. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 2009; 8: 4844-4850 [PMID: 19678709 DOI: 10.1021/pr9004162]
33. Meyer LH, Debatin KM. Diversity of human leukemia xenograft mouse models: implications for disease biology. Cancer Res 2011; 71: 7141-7144 [PMID: 22088964 DOI: 10.1158/0008-5472.can-11-1732]
34. Raheem O, Kulidjian AA, Wu C, Jeong YB, Yamaguchi T, Smith KM, Goff D, Leu H, Morris SR, Cacalano NA, Masuda K, Jamieson CH, Kane CJ, Jamieson CA. A novel patientderived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions. J Transl Med 2011; 9: 185 [PMID: 22035283 DOI: 10.1186/1479-5876-9-185]
35. Jia Y, Liu M, Huang W, Wang Z, He Y, Wu J, Ren S, Ju Y, Geng R, Li Z. Recombinant human endostatin endostar inhibits tumor growth and metastasis in a mouse xenograft model of colon cancer. Pathol Oncol Res 2012; 18: 315-323 [PMID: 21938482 DOI: 10.1007/s12253-011-9447-y]
36. Hui X, Chen H, Zhang S, Ma X, Wang X, Huang B. Antitumor activities of recombinant human interferon (IFN)-λ1 in vitro and in xenograft models in vivo for colon cancer. Cancer Lett 2011; 311: 141-151 [PMID: 21872388 DOI: 10.1016/ j.canlet.2011.07.004]
37. Huynh H, Choo SP, Toh HC, Tai WM, Chung AY, Chow PK, Ong R, Soo KC. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. Curr Cancer Drug Targets 2011; 11: 944-953 [PMID: 21834756]
38. Liang F, Wang MY, Huang WB, Li AJ. [Effect of sodium cantharidinate on the angiogenesis of nude mice with human gastric cancer]. Zhong Yao Cai 2011; 34: 343-346 [PMID: 21823448]
39. Issaq HJ, Fox SD, Chan KC, Veenstra TD. Global proteomics and metabolomics in cancer biomarker discovery. J Sep Sci 2011; 34: 3484-3492 [PMID: 22102289 DOI: 10.1002/ jssc.201100528]
40. Issaq HJ, Abbott E, Veenstra TD. Utility of separation science in metabolomic studies. J Sep Sci 2008; 31: 1936-1947 [PMID: 18348322 DOI: 10.1002/jssc.200700601]
41. Wang QZ, Wu CY, Chen T, Chen X, Zhao XM. Integrating metabolomics into a systems biology framework to exploit metabolic complexity: strategies and applications in microorganisms. Appl Microbiol Biotechnol 2006; 70: 151-161 [PMID: 16395543 DOI: 10.1007/s00253-005-0277-2]
42. Dunn WB, Bailey NJ, Johnson HE. Measuring the metabolome: current analytical technologies. Analyst 2005; 130: 606-625 [PMID: 15852128 DOI: 10.1039/b418288j]
43. Ippolito JE, Xu J, Jain S, Moulder K, Mennerick S, Crowley JR, Townsend RR, Gordon JI. An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad Sci USA 2005; 102: 9901-9906 [PMID: 15998737 DOI: 10.1073/ pnas.0500756102]
44. Odunsi K, Wollman RM, Ambrosone CB, Hutson A, Mc-Cann SE, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W, Qian F, Keitz B, Intengan M, Lele S, Alderfer JL. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics. Int J Cancer 2005; 113: 782-788 [PMID: 15499633 DOI: 10.1002/ijc.20651]
45. Yan SK, Wei BJ, Lin ZY, Yang Y, Zhou ZT, Zhang WD. A metabonomic approach to the diagnosis of oral squamous cell carcinoma, oral lichen planus and oral leukoplakia. Oral Oncol 2008; 44: 477-483 [PMID: 17936673 DOI: 10.1016/j.oral oncology.2007.06.007]
46. Nicholson JK, Connelly J, Lindon JC, Holmes E. Metabonomics: a platform for studying drug toxicity and gene function. Nat Rev Drug Discov 2002; 1: 153-161 [PMID: 12120097 DOI: 10.1038/nrd728]
47. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 2004; 9: 1-31 [PMID: 15204308 DOI: 10.1080/13547500410001668379]
48. Lindon JC, Holmes E, Nicholson JK. Metabonomics: systems biology in pharmaceutical research and development. Curr Opin Mol Ther 2004; 6: 265-272 [PMID: 15264428]
49. Clayton TA, Lindon JC, Cloarec O, Antti H, Charuel C, Hanton G, Provost JP, Le Net JL, Baker D, Walley RJ, Everett JR, Nicholson JK. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006; 440: 1073-1077 [PMID: 16625200 DOI: 10.1038/nature04648]
50. Di Leo A, Claudino W, Colangiuli D, Bessi S, Pestrin M, Biganzoli L. New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer. Ann Oncol 2007; 18 Suppl 12: xii8-xi14 [PMID: 18083700 DOI: 10.1093/annonc/mdm533]
51. Nicholson JK, Lindon JC. Systems biology: Metabonomics. Nature 2008; 455: 1054-1056 [PMID: 18948945 DOI: 10.1038/4551054a]
52. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics--a review in human disease diagnosis. Anal Chim Acta 2010; 659: 23-33 [PMID: 20103103 DOI: 10.1016/ j.aca.2009.11.042]
53. Griffin JL, Kauppinen RA. Tumour metabolomics in animal models of human cancer. J Proteome Res 2007; 6: 498-505 [PMID: 17269706 DOI: 10.1021/pr060464h]
54. Spratlin JL, Serkova NJ, Eckhardt SG. Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 2009; 15: 431-440 [PMID: 19147747 DOI: 10.1158/1078-0432. ccr-08-1059]
55. Blekherman G, Laubenbacher R, Cortes DF, Mendes P, Torti FM, Akman S, Torti SV, Shulaev V. Bioinformatics tools for cancer metabolomics. Metabolomics 2011; 7: 329-343 [PMID: 21949492 DOI: 10.1007/s11306-010-0270-3]
56. Barderas MG, Laborde CM, Posada M, de la Cuesta F, Zubiri I, Vivanco F, Alvarez-Llamas G. Metabolomic profiling for identification of novel potential biomarkers in cardiovascular diseases. J Biomed Biotechnol 2011; 2011: 790132 [PMID: 21274272 DOI: 10.1155/2011/790132]
57. Jain KK. The Handbook of Biomarkers. 1st ed: Springer Science, 2010
58. Serkova NJ, Glunde K. Metabolomics of cancer. Methods Mol Biol 2009; 520: 273-295 [PMID: 19381962 DOI: 10.1007/978-1-60327-811-9_20]
59. Jordan KW, Cheng LL. NMR-based metabolomics approach to target biomarkers for human prostate cancer. Expert Rev Proteomics 2007; 4: 389-400 [PMID: 17552923 DOI: 10.1586/14 789450.4.3.389]
60. Chen Y, Zhang R, Song Y, He J, Sun J, Bai J, An Z, Dong L, Zhan Q, Abliz Z. RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer. Analyst 2009; 134: 2003-2011 [PMID: 19768207 DOI: 10.1039/ b907243h]
61. Asiago VM, Alvarado LZ, Shanaiah N, Gowda GA, Owusu-Sarfo K, Ballas RA, Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res 2010; 70: 8309-8318 [PMID: 20959483 DOI: 10.1158/0008-5472. can-10-1319]
62. Yang Q, Shi X, Wang Y, Wang W, He H, Lu X, Xu G. Urinary metabonomic study of lung cancer by a fully automatic hyphenated hydrophilic interaction/RPLC-MS system. J Sep Sci 2010; 33: 1495-1503 [PMID: 20309903 DOI: 10.1002/ jssc.200900798]
63. Johnson HE, Broadhurst D, Goodacre R, Smith AR. Metabolic fingerprinting of salt-stressed tomatoes. Phytochemistry 2003; 62: 919-928 [PMID: 12590119]
64. Kim DH, Jarvis RM, Xu Y, Oliver AW, Allwood JW, Hampson L, Hampson IN, Goodacre R. Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir. Analyst 2010; 135: 1235-1244 [PMID: 20390218 DOI: 10.1039/b923046g]
65. Itoh A, Ohashi Y, Soga T, Mori H, Nishioka T, Tomita M. Application of capillary electrophoresis-mass spectrometry to synthetic in vitro glycolysis studies. Electrophoresis 2004; 25: 1996-2002 [PMID: 15237399 DOI: 10.1002/elps.200305905]
66. Soga T. Capillary electrophoresis-mass spectrometry for metabolomics. Methods Mol Biol 2007; 358: 129-137 [PMID: 17035684]
67. Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, Nishioka T. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2003; 2: 488-494 [PMID: 14582645]
68. Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M. Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancerspecific profiles. Metabolomics 2010; 6: 78-95 [PMID: 20300169 DOI: 10.1007/s11306-009-0178-y]
69. Lenz EM, Bright J, Wilson ID, Morgan SR, Nash AF. A 1H NMR-based metabonomic study of urine and plasma samples obtained from healthy human subjects. J Pharm Biomed Anal 2003; 33: 1103-1115 [PMID: 14656601]
70. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci USA 1999; 96: 2907-2912 [PMID: 10077610]
71. Raamsdonk LM, Teusink B, Broadhurst D, Zhang N, Hayes A, Walsh MC, Berden JA, Brindle KM, Kell DB, Rowland JJ, Westerhoff HV, van Dam K, Oliver SG. A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations. Nat Biotechnol 2001; 19: 45-50 [PMID: 11135551 DOI: 10.1038/83496]
72. Musumarra G, Barresi V, Condorelli DF, Scirè S. A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics. Biol Chem 2003; 384: 321-327 [PMID: 12675527 DOI: 10.1515/ bc.2003.037]
73. Kubota T, Weisenthal L. Chemotherapy sensitivity and resistance testing: to be "standard" or to be individualized, that is the question. Gastric Cancer 2006; 9: 82-87 [PMID: 16767362 DOI: 10.1007/s10120-006-0366-7]
74. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; (3) CD004064 [PMID: 20238327 DOI: 10.1002/14651858.CD004064.pub3]
75. Wang X, Yan SK, Dai WX, Liu XR, Zhang WD, Wang JJ. A metabonomic approach to chemosensitivity prediction of cisplatin plus 5-fluorouracil in a human xenograft model of gastric cancer. Int J Cancer 2010; 127: 2841-2850 [PMID: 21351263 DOI: 10.1002/ijc.25294]
76. Sikora K. Personalized cancer therapy--the key to the future. Pharmacogenomics 2004; 5: 225-228 [PMID: 15102537 DOI: 10.1517/phgs.5.3.225.29829]
77. Sikora K. Personalized medicine for cancer: from molecular signature to therapeutic choice. Adv Cancer Res 2007; 96: 345-369 [PMID: 17161685 DOI: 10.1016/s0065-230x(06)96013-8]
78. Park DJ, Lenz HJ. Determinants of chemosensitivity in gastric cancer. Curr Opin Pharmacol 2006; 6: 337-344 [PMID: 16777480 DOI: 10.1016/j.coph.2006.05.002]
79. McLeod HL. Individualized cancer therapy: molecular approaches to the prediction of tumor response. Expert Rev Anticancer Ther 2002; 2: 113-119 [PMID: 12113060 DOI: 10.158 6/14737140.2.1.113]
80. Garman KS, Nevins JR, Potti A. Genomic strategies for personalized cancer therapy. Hum Mol Genet 2007; 16 Spec No. 2: R226-R232 [PMID: 17911165 DOI: 10.1093/hmg/ddm184]
81. Ma Y, Ding Z, Qian Y, Shi X, Castranova V, Harner EJ, Guo L. Predicting cancer drug response by proteomic profiling. Clin Cancer Res 2006; 12: 4583-4589 [PMID: 16899605 DOI: 10.1158/1078-0432.ccr-06-0290]
82. Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, Madhusudan S. Biomarkers of response to therapy in oesophago-gastric cancer. Gut 2009; 58: 127-143 [PMID: 19091831 DOI: 10.1136/gut.2008.155861]
83. Brereton RG. Chemometrics: data analysis for the laboratory and chemical plant. USA: John Wiley & Sons, 2003
84. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 2009; 50 Suppl: S237-S242 [PMID: 19011112 DOI: 10.1194/jlr.R800033-JLR200]
85. Burke JE, Dennis EA. Phospholipase A2 biochemistry. Cardiovasc Drugs Ther 2009; 23: 49-59 [PMID: 18931897 DOI: 10.1007/s10557-008-6132-9]
86. Kent C. Regulatory enzymes of phosphatidylcholine biosynthesis: a personal perspective. Biochim Biophys Acta 2005; 1733: 53-66 [PMID: 15749057 DOI: 10.1016/ j.bbalip.2004.12.008]
87. Lands WE. Stories about acyl chains. Biochim Biophys Acta 2000; 1483: 1-14 [PMID: 10601692]
88. Jackson SK, Abate W, Tonks AJ. Lysophospholipid acyltransferases: novel potential regulators of the inflammatory response and target for new drug discovery. Pharmacol Ther 2008; 119: 104-114 [PMID: 18538854 DOI: 10.1016/j.pharmthe ra.2008.04.001]
89. Takikawa M, Akiyama Y, Maruyama K, Suzuki A, Liu F, Tai S, Ohshita C, Kawaguchi Y, Bandou E, Yonemura Y, Yamaguchi K. Proteomic analysis of a highly metastatic gastric cancer cell line using two-dimensional differential gel electrophoresis. Oncol Rep 2006; 16: 705-711 [PMID: 16969483]
90. Chen JL, Tang HQ, Hu JD, Fan J, Hong J, Gu JZ. Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry. World J Gastroenterol 2010; 16: 5874-5880 [PMID: 21155010 DOI: 10.3748/wjg.v16.i46.5874]
91. Hu JD, Tang HQ, Zhang Q, Fan J, Hong J, Gu JZ, Chen JL. Prediction of gastric cancer metastasis through urinary metabolomic investigation using GC/MS. World J Gastroenterol 2011; 17: 727-734 [PMID: 21390142 DOI: 10.3748/wjg.v17. i6.727]
92. Liu X, Wang X, Zhang J, Lam EK, Shin VY, Cheng AS, Yu J, Chan FK, Sung JJ, Jin HC. Warburg effect revisited: an epigenetic link between glycolysis and gastric carcinogenesis. Oncogene 2010; 29: 442-450 [PMID: 19881551 DOI: 10.1038/ onc.2009.332]
93. Chen JL, Fan J, Tang HQ, Hu JD, Gu JZ. Urinary Metabolomic Analysis of Human Gastric Cancer Mouse Models and Patients Using Gas Chromatography/Mass Spectrometry. J Mol Biomark Diagn 2011; 1-8
94. Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC, Chen JH. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol 2007; 14: 84-93 [PMID: 17063306 DOI: 10.1245/s10434-006-9091-z]
95. Wang CS, Wu TL, Tsao KC, Sun CF. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Ann Clin Lab Sci 2006; 36: 23-30 [PMID: 16501233]
96. Kim KB, Yang JY, Kwack SJ, Park KL, Kim HS, Ryu do H, Kim YJ, Hwang GS, Lee BM. Toxicometabolomics of urinary biomarkers for human gastric cancer in a mouse model. J Toxicol Environ Health A 2010; 73: 1420-1430 [PMID: 20954069 DOI: 10.1080/15287394.2010.511545]
97. Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, Yang S, Shi R. Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol 2011; 26: 1290-1297 [PMID: 21443661 DOI: 10.1111/j.1440-1746.2011.06724.x]
98. Song H, Peng JS, Dong-Sheng Y, Yang ZL, Liu HL, Zeng YK, Shi XP, Lu BY. Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res 2012; 45: 78-85 [PMID: 22124703]
99. Wu H, Xue R, Tang Z, Deng C, Liu T, Zeng H, Sun Y, Shen X. Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. Anal Bioanal Chem 2010; 396: 1385-1395 [PMID: 20012946 DOI: 10.1007/ s00216-009-3317-4]
100. Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, Bamba T, Fukusaki E, Takenawa T, Azuma T, Yoshida M. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr 2012; 26: 548-558 [PMID: 21773981 DOI: 10.1002/bmc.1671]
101. Holdstock G, Bruce S. Endoscopy and gastric cancer. Gut 1981; 22: 673-676 [DOI: 10.1136/gut.22.8.673]
102. Layke JC, Lopez PP. Gastric cancer: diagnosis and treatment options. Am Fam Physician 2004; 69: 1133-1140 [PMID: 15023013]
103. Akagi T, Shiraishi N, Kitano S. Lymph Node Metastasis of Gastric Cancer. Cancers 2011; 3: 2141-2159 [DOI: 10.3390/cancers3022141]
104. Nakamura R, Saikawa Y, Kubota T, Kumagai A, Kiyota T, Ohashi M, Yoshida M, Otani Y, Kumai K, Kitajima M. Role of the MTT chemosensitivity test in the prognosis of gastric cancer patients after postoperative adjuvant chemotherapy. Anticancer Res 2006; 26: 1433-1437 [PMID: 16619555]
105. Grivet JP, Delort AM, Portais JC. NMR and microbiology: from physiology to metabolomics. Biochimie 2003; 85: 823-840 [PMID: 14652172]
106. Devantier R, Scheithauer B, Villas-Bôas SG, Pedersen S, Olsson L. Metabolite profiling for analysis of yeast stress response during very high gravity ethanol fermentations. Biotechnol Bioeng 2005; 90: 703-714 [PMID: 15812801 DOI: 10.1002/bit.20457]
107. Schauer N, Steinhauser D, Strelkov S, Schomburg D, Allison G, Moritz T, Lundgren K, Roessner-Tunali U, Forbes MG, Willmitzer L, Fernie AR, Kopka J. GC-MS libraries for the rapid identification of metabolites in complex biological samples. FEBS Lett 2005; 579: 1332-1337 [PMID: 15733837 DOI: 10.1016/j.febslet.2005.01.029]
108. Buchholz A, Takors R, Wandrey C. Quantification of intracellular metabolites in Escherichia coli K12 using liquid chromatographic-electrospray ionization tandem mass spectrometric techniques. Anal Biochem 2001; 295: 129-137 [PMID: 11488613 DOI: 10.1006/abio.2001.5183]
109. Smedsgaard J, Nielsen J. Metabolite profiling of fungi and yeast: from phenotype to metabolome by MS and informatics. J Exp Bot 2005; 56: 273-286 [PMID: 15618299 DOI: 10.1093/jxb/eri068]
110. Ellis DI, Broadhurst D, Kell DB, Rowland JJ, Goodacre R. Rapid and quantitative detection of the microbial spoilage of meat by fourier transform infrared spectroscopy and machine learning. Appl Environ Microbiol 2002; 68: 2822-2828 [PMID: 12039738]
111. Kaderbhai NN, Broadhurst DI, Ellis DI, Goodacre R, Kell DB. Functional genomics via metabolic footprinting: monitoring metabolite secretion by Escherichia coli tryptophan metabolism mutants using FT-IR and direct injection electrospray mass spectrometry. Comp Funct Genomics 2003; 4: 376-391 [PMID: 18629082 DOI: 10.1002/cfg.302]